July 17, 2020
Gmail users: to ensure you're always viewing the entire newsletter, check at the bottom of the email to see if the newsletter has been "clipped" and click "view entire message" if so.
From the School of Medicine
Support the NIH and Dr. Fauci
Yesterday, the Association of American Cancer Institutes (AACI) reminded our nation how fundamental the lifesaving work of the National Institutes of Health (NIH) is to our strength and well-being. Please read the AACI’s press release here.

Through its careful deliberation to generate high-quality, data-driven discovery and implementation under Dr. Anthony Fauci’s lead, the NIH is empowering us to better understand and effectively manage the worldwide COVID-19 pandemic. Along with many other healthcare professionals, our researchers, scientists and clinicians are working under circumstances of incalculable unknowns to control and ultimately eradicate this highly contagious virus capable of infecting and killing any and all of us.

Reliance on discovery and rapid dissemination of the very best evidence is what we expect, what we do, and what we will continue to do. Dr. Fauci, a friend and world-renowned and respected expert, has taken on incredible risk to defend us in our pursuits to combat COVID-19 in the lab, in the clinic and on the street.

He deserves our unequivocal support.

Stan Gerson, MD
Interim Dean, School of Medicine
Director, Case Comprehensive Cancer Center
Case Western Reserve University
Mourning the loss of Benigno Rodriguez, MD
Earlier this week, were devastated to learn about the death of Benigno Rodriguez, an associate professor and exceptional principal investigator for HIV/AIDS research.

Benigno worked with the Case AIDS Clinical Trials Unit, achieving groundbreaking work toward understanding the mechanisms of HIV-related diseases and developing techniques to reset the immune system by rendering the cells resistant to the virus that causes AIDS. The unit’s efforts are quite unique across the country and the team’s impact has been incredibly positive for our community and our researchers. Benigno was devoted to the unit and made it his priority to recognize the team as key to achieving such outstanding success toward the fight against HIV/AIDS.

In addition to leading innovative trials and studies related to HIV/AIDS, Benigno was a very caring and empathetic colleague and friend. We send our heartfelt condolences to his family, friends, colleagues, and everyone who knew and loved Benigno.
Member/Center Highlights
Cancer Data Sciences Initiative
We are thrilled to announce the launching of a new pillar for the Case Comprehensive Cancer Center (Case CCC) in Cancer Data Sciences.

The Cancer Data Sciences pillar will serve as a discipline in the Case CCC to standardize and organize data for optimal use and leverage advanced analytic approaches to enable independent and synergistic research for basic, clinical, population and translation sciences. This effort will tap into the potential of Case CCC members to drive new analytical capabilities and develop novel algorithms in order to mine and extract knowledge from complex cancer data for maximal impact.

We are looking to establish a Cancer Data Sciences Community so we can learn from each other and advance science in this discipline together. Please indicate in this short form if you would like to be part of the Cancer Data Sciences Community. Another form will follow to indicate your time/date preference to schedule an introductory meeting.

The Case CCC Cancer Data Sciences Leadership Team
Jill Barnholtz-Sloan, PhD, Case CCC Associate Director for Data Sciences
Sharon L. Stein, MD FACS FASCRS
Vinay Varadan, PhD 
Aziz Nazha, MD
Paola Saroufim, PharmD, MPH, MBA
Virtual Velosano Weekend Begins Today!
It's here! The hottest month of the year and typically one of the most exciting events the Case Comprehensive Cancer Center participates in each July - VeloSano! Team Case CCC currently has 40 passionate members dedicated to the cause and we hope you'll join or support our efforts! Our wonderful riders and virtual riders join us from all Case Comprehensive Cancer Center partners - University Hospitals, Case Western Reserve University and the Cleveland Clinic and represent a wide spectrum of professions... physicians, researchers, physician-researchers, hospital administrators, graduate students, even family and friends!

This weekend, Virtual VeloSano participants will complete and log their chosen activities for the year-round fundraising initiative (if they haven't done so already). Many will continue on their bikes, while others have chosen to log runs, walks, kayaking... even gardening! Donations to Team Case CCC can be made through October 1, 2020.
Here's a look at Virtual VeloSano weekend - we can't wait to see your pictures!

Virtual elements will make it easy to participate from wherever you are, including but not limited to:

  • Virtual Kickoff Party streaming live - tune in tonight at velosano.org!
  • Virtual VeloSano “Day” on Saturday, July 18
  • Virtual “starting line” to kick things off on Saturday, July 18
  • Participate in your activity of choice wearing your VeloSano 7 jersey or T-shirt
  • Share on social media using #VirtualVeloSano and be featured throughout the day (and beyond!) - be sure to tag @caseccc or #TeamCaseCCC, too!
  • Share your pictures with the Case CCC communications team so we can compile a group photo! Simply send them to cancer@case.edu
  • Virtual “Group Photos” for Big Wheeler, Living Hope and frontline caregivers
  • Share your “Why I VeloSano” message on the Dedication Wall on velosano.org
Case Comprehensive Cancer Center Spring 2020 Pilot Awardees
William Schiemann
Accelerator Award
1 year, $120,000 support

Project: BORG:TRIM28 Complexes: Global Regulators of Alternative mRNA Splicing Coupled to BCSC Plasticity and Metastatic Relapse
Cancer Innovation Award
1 year, $75,000 support


Project: Extracellular Vesicles for the Early Detection of Breast Cancer
Chakraborty
Jumpstart Award
18 months, $75,000 support


Project: Investigating Kidney Lineage-Specific Genetic Dependencies as Anti-Cancer Targets in Renal Cancer
Lung Cancer Pilot Award
1 year, $50,000 support

Project: Role of PIP2 and Gasdermin D in lung cancer progression and metastasis
American Cancer Society IRG Award
1 year, $40,000 support

Project: HCMV-encoded GPCRs: Potential targets for preventing reactivation in BMT patients
Second Annual TED-Style Talks LIVE at 12 pm ET next Thursday, July 23
In less than a week, we will host our second annual TED-style talks from three prominent leaders of research and advocacy as part of our Annual Scientific Retreat! These three leaders in their fields will share their insights from decades of experience cultivating community, challenging the status quo, and always seeking to better humankind.

All are invited to tune into these LIVE talks, beginning at 12 pm ET on Thursday, July 23 and broadcast at case.edu/livestream/s1. ( We ask that Case CCC members who have registered for retreat log in to the Zoom details provided via email early next week so we can record your attendance.)
Associate Director for Data Sciences, Case Comprehensive Cancer Center

"GO TEAM! How Team Science Creates Scientific Impact"
Vice Chairman, Department of Pediatric Surgery,
University Hospitals

"Antifragility: Beyond Resilience"
Founder & CEO, MTN Strategies
Founder & Strategic Advisor, The Gathering Place

"What is your why?"
Nieman appointed Interim Associate Dean for Graduate Education
Marvin Nieman, PhD has been appointed as Interim Associate Dean for Graduate Education at Case Western Reserve University School of Medicine, announced Mark Chance, PhD, Vice Dean for Research this Wednesday. Joining the School of Medicine in 2006, Marvin most recently served as Graduate Program Director in the Department of Pharmacology where he led the implementation of a competency-based curriculum for the PhD program. He is an associate professor in the Department of Pharmacology and a member of the Case Comprehensive Cancer Center.
Ramakrishnan selected for American Association of Immunologists Public Policy Fellows Program
From The Daily: Parameswaran Ramakrishnan, PhD, MS, assistant professor of pathology and biochemistry, was selected as one of the 10 fellows in the American Association of Immunologists (AAI) Public Policy Fellows Program for the year 2020-21.

Fellows will attend a two-day Capitol Hill Day in Washington, D.C. They take part in a training session with AAI staff and visit their Congressional representatives to advocate for biomedical research and increased funding for the National Institutes of Health.

Dr. Ramakrishnan is a member of the Case Comprehensive Cancer Center's Hematopoietic and Immune Cancer Biology Program.
Hwang awarded NanoString GeoMx Cancer Transcriptome Atlas Grant
Congratulations to Cleveland Clinic's Tae Hyun Hwang, PhD as he recently received one of five NanoString Cancer Transcriptome Atlas Grants.

Dr. Hwang was awarded for his submission, " Investigating mechanisms of response and resistance to immune checkpoint therapy in stomach cancer." He is a member of the Case Comprehensive Cancer Center's GU Malignancies Program.
Case CCC COVID-19 Resource Hub
As the COVID-19 outbreak progresses, the Case Comprehensive Cancer Center (Case CCC) has centralized COVID-19 related news, resources and funding opportunities for our cancer center community. Content is updated regularly.

To have a cancer-focused resource added to the page, please email  cancer@case.edu.
What's Coming Up
Mark Your Calendar
This Weekend! Virtual VeloSano
July 17-18, 2020

VeloSano is more than a fundraising event. It's more than simply a bike ride, and this year, it has gone virtual! VeloSano is a movement with the goal of bringing an entire community together to help one another. The Case Comprehensive Cancer Center (Case CCC) is honored to participate for its sixth year in a row. Together, our team of Case CCC employees and friends are once again joining the movement to raise money for the cause. Team Case CCC is made of passionate individuals who are committed to cancer research, prevention, treatment, and cures! 100% of the money we raise will support lifesaving cancer research in Northeast Ohio's top-tier hospitals and research institutions.

Virtual VeloSano has no fundraising minimums or registration fees and "riders" are able to track their participation in their favorite activity such as biking, hiking, swimming, even gardening any time between now and October 1. VeloSano's signature "Bike to Cure" weekend will still take place virtually, complete with a streaming Kickoff Party and more!

Although we won't be able to unite in person, the need to fund cancer research remains more important than ever. We look forward to seeing our team's virtual participation through photos and videos on social media using hashtag #TeamCaseCCC or tags to @caseccc as we train and rally together remotely. Our continuing goal is to bring sustainable funding to cancer research by enlisting the passion and energy of thousands of people who wish to give back…including YOU! We raised nearly $94,000 last year and our team's participation has collectively brought more than $1,500,000 back to the Case CCC for funding of 31 pilot research projects. We are truly grateful for your commitment to the cause and hope you will join or support our efforts this year!
Final Call for Registration: Virtual Annual Scientific Retreat
July 23-24, 2020

The Case Comprehensive Cancer Center invites all members and trainees to join us Thursday, July 23 and Friday, July 24, 2020 for our annual scientific retreat! This year's retreat will be held virtually.

Thursday's events are scheduled from 12-2:30pm including TED-style talks from prominent Cleveland researchers and a cancer center update from Director Stan Gerson, MD. All are welcome to attend Thursday's session, though registration is required for members to receive virtual access.

Friday's member and trainee session will begin at 12:00 pm with a keynote presentation from Timothy Rebbeck, PhD, the Vincent L. Gregory, Jr. Professor of Cancer Prevention at the Harvard T.H. Chan School of Public Health and the Dana-Farber Cancer Institute.

Dr. Rebbeck is founding director of the Zhu Family Center for Global Cancer Prevention at the Harvard TH Chan School of Public Health and leads the Cancer Outreach and Engagement activities for the Dana-Farber Harvard Cancer Center. He will present, "Confronting Cancer Health Disparities: From Cells to Society."

Following a short break, members will then gather in Zoom breakout sessions for their assigned research programs for discussion of initiatives, collaborations and cancer center support of projects through pilots and shared resources.

Please note there will not be a trainee virtual breakout session on Friday, however a bench-to-bedside retreat is being planned for the Spring 2021. More information is forthcoming.

Retreat registration is now open. Please contact Mary Wright at maw143@case.edu) with any questions.
Early Bird Registration Now Open: Artificial Intelligence in Oncology Symposium 2020
October 19-20, 2020

The second annual Artificial Intelligence in Oncology Symposium will bring together experts in AI and machine learning as well as clinical, industry and federal agency experts in pathology, radiology, drug discovery, and ethics and policy to speak on research developments, regulatory policy, reimbursement and ethics surrounding AI in oncology. For the health and safety of all attendees, this year's symposium will take place virtually.

The symposium will feature four focused sessions, with speakers and panel discussions providing unique perspectives on how AI and machine learning are impacting the major areas of radiology, pathology and -omics in the contexts of precision medicine approaches for characterizing tumors and predicting therapeutic response.

Beyond the science, attendees are invited to view a poster session from some of brightest rising stars in the field of AI in oncology.

Geraldine McGinty, MD, MBA, FACR will present the symposium plenary, "Fostering a Strong Ecosystem for AI in Medical Imaging." Dr. McGinty is an internationally recognized expert in imaging economics, Chair of the American College of Radiology Board of Chancellors and Chief Strategy and Contracting Officer at Weill Cornell Medicine in New York City.

Additional keynotes in drug discovery, ethics & policy and pathology will be delivered by Russ Altman, MD, PhD of Stanford University, Aashima Gupta, MS of Google, Vinay Prasad, MD, MPH of the University of California, San Francisco, and Yinyin Yuan, PhD of the Institute of Cancer Research, London. Learn more about AIO 2020 speakers.
Additional Upcoming Events
AACR
AACR Virtual Meeting: COVID-19 and Cancer
July 20-22, 2020
This special AACR conference will focus on the presentation of emerging data in basic, clinical, and epidemiologic research related to COVID-19 and cancer. The program will feature a mix of keynote lectures and other invited presentations, short talks from highly rated abstracts, virtual posters, and forums that include panels of experts from various fields. It is anticipated that this must-attend virtual event will attract participants from across the international research community.
Society of Neuro-Oncology Virtual Conference on Brain Metastases
August 14, 2020
The Society for Neuro-Oncology, in association with the AANS/CNS Section on Tumors, is pleased to announce its virtual Conference on Brain Metastases.

This live event will feature select abstract presentations and invited lectures from the originally scheduled in-person meeting which was set to take place in Toronto. Join the exciting and diverse program on August 14, 2020, from 11am - 4pm (US ET).
NCCN Oncology Policy Virtual Summit
 September 9, 2020
The Summit will explore diverse perspectives related to emerging models to drive down healthcare costs in the United States and their potential impact on access to high-quality cancer care. Major themes of the summit will include an overview of legislative and regulatory efforts to reduce health costs, the current state of value-based payment models, and the impact of these models on providers and patients with cancer. The summit will also explore the unique implications of policies intended to curb costs for rural and other underserved populations.

If you have any questions, please contact Terrell Johnson, Manager, Policy and Advocacy, johnson@nccn.org.
NCCN 2021 Annual Conference: Call for Abstracts
Abstract Deadline: November 11, 2020
NCCN is now accepting abstracts for consideration to be presented during the NCCN 2021 Annual Conference General Poster Session at the Rosen Shingle Creek in Orlando, Florida on Thursday, March 18 and Friday, March 19, 2021. NCCN welcomes original abstracts from investigators in the general oncology community. Submissions will be accepted from academic institutions, teaching and community hospitals, or industry. Both NCCN and non-NCCN institutions may participate.

Research may fall into the general areas below:

  • Clinical Oncology (all phases)
  • Pre-Clinical Oncology
  • Epidemiology/Risks/Prevention
  • Correlative/Genomic
  • Best Practices in Implementation and Use of Clinical Practice Guidelines
  • Quality Improvement
  • Outcomes and Health Services Research
  • Bioinformatics/Information Technology Sciences
Funding Opportunities
Deadline: August 1, 2020
To improve the discovery and advancement of innovative cancer therapeutics, the Case Comprehensive Cancer Center (Case CCC) has initiated a Drug Discovery Initiative and is providing seed funding toward the development of novel cancer therapeutics. To access funding, investigators must participate in the decennial Case CCC Drug Discovery Census. All therapeutic approaches and modalities are welcome! Projects at all stages are welcome! BE COUNTED! The Census is simple to complete and open to all Case CCC Members. Applications will be accepted until August 1, 2020.

Award Description
  • Awards will be milestone-based and project-specific.
  • Our aim is to select a number of projects for seed funding and to continue to support projects that achieve key milestones.
  • Total funds committed to this RFA are $250,000.
  • Note that projects proposing small-molecule approaches will be considered for additional funding opportunities.
LOI Deadline: September 9, 2020
National Comprehensive Cancer Network® (NCCN®) is pleased to announce that it is collaborating with Pfizer Global Medical Grants (Pfizer) to offer a new grant opportunity in support of biosimilars in oncology. The intent of this RFP is to encourage organizations in the United States to submit initial Letters of Intent (LOIs) describing concepts that develop and validate enduring approaches to improve the safe, effective and efficient adoption of biosimilars in oncology. LOIs that directly measure increases in biosimilar use or improve safety, value and efficiency in both academic and/or community-based oncology practices will be prioritized. The sustainability and broad applicability of the approach, and its potential to add value to cancer care delivery, will be key factors in evaluating fundable projects. Update: Please note that this document can be accessed online.

To be considered for funding, LOIs must be submitted by 11:59 pm ET on Wednesday, September 9, 2020. Please direct questions regarding this RFP to Nicole Kamienski at kamienski@nccn.org with the subject line, “2020 Biosimilars Project.”
In The News
Healthline - July 12, 2020
“We ask who they’ve been in contact with in the 48 hours prior to symptom onset, or 2 days before the date of their positive test if they don’t have symptoms,” said Dr. Heidi Gullett, associate director of the Center for Community Health Integration at the Case Western Reserve University School of Medicine and medical director of the Cuyahoga County Board of Health in Ohio. Dr. Gullett is a member of the Cancer Prevention Control & Population Research Program at the Case Comprehensive Cancer Center.
LiveScience - July 12, 2020
"When it comes to at-home UVC lamps, their ability to damage skin and eyes isn't the only danger, Dr. Jacob Scott, a research physician in the Department of Translational Hematology and Oncology Research at Cleveland Clinic, said. These devices also have low quality control, which means there's no guarantee that you're actually eliminating the pathogen, he said." Dr. Scott is a member of the Case CCC's Developmental Therapeutics Program.
From The NIH
Weekly NIH Funding Opportunities and Notices
Notices



Funding Opportunities
Standard dates apply

Standard dates apply

Standard dates apply

Standard dates apply

Deadlines for new submissions: October 02, 2020; June 02, 2021; October 04, 2021; June 02, 2022; October 03, 2022; June 02, 2023
Deadlines for resubmissions: October 19, 2020; June 17, 2021; October 19, 2021; June 17, 2022; October 19, 2022; June 19, 2023
COVID-19 Funding Opportunities and Notices
Have something to share?
Use the button below to submit all your news, publications, events, announcements, lab openings and communications requests to the Case CCC Marketing and Communications team! We are here to help.